![Elena Ridloff](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Elena Ridloff
Finansdirektör/CFO på
SIONNA THERAPEUTICS, INC.
Förmögenhet: 699 943 $ per 2026-09-30
Profil
Ms. Elena H.
Ridloff, CFA, is an Independent Director at Kymera Therapeutics, Inc. and a Chief Financial Officer & Chief Business Officer at Sionna Therapeutics, Inc. She is on the Board of Directors at Immunic, Inc. and Kymera Therapeutics, Inc. Ms. Ridloff was previously employed as an Independent Director by Kronos Bio, Inc., a Chief Financial Officer & Executive Vice President by ACADIA Pharmaceuticals, Inc., a Vice President-Investor Relations by Alexion Pharmaceuticals, Inc., a Chief Executive Officer & Managing Member by BioVision, Inc., a Senior Analyst by Maverick Capital Ltd., a Senior Analyst by Paramount BioCapital Asset Management, Inc., and a Chief Financial Officer by Stealth BioTherapeutics, Inc. She received her undergraduate degree from the University of Pennsylvania.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-09-17 | 133 069 ( 0,29 % ) | 699 943 $ | 2026-09-30 | |
IMMUNIC, INC. -.--% | 2026-08-06 | 0 ( -.--% ) | - $ | 2026-09-30 |
Aktiva positioner av Elena Ridloff
| Företag | Position | Start |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Direktör/Styrelseledamot | 2021-03-12 |
| SIONNA THERAPEUTICS, INC. | Finansdirektör/CFO | 2021-01-01 |
| IMMUNIC, INC. | Direktör/Styrelseledamot | 2026-08-06 |
Tidigare kända positioner av Elena Ridloff
| Företag | Position | Slut |
|---|---|---|
| KRONOS BIO, INC. | Direktör/Styrelseledamot | 2025-06-20 |
| ACADIA PHARMACEUTICALS INC. | Finansdirektör/CFO | 2021-09-10 |
| ALEXION PHARMACEUTICALS, INC. | Investor Relations Kontakt | 2018-03-01 |
BioVision, Inc.
 BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Verkställande Direktör | 2014-04-01 |
Maverick Capital Ltd.
 Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Analyst-Equity | 2012-01-01 |
Elena Ridloffs utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
78
Första gradens relationer
11
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 11 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Paramount BioCapital Asset Management, Inc.
 Paramount BioCapital Asset Management, Inc. Investment ManagersFinance Paramount BioCapital Asset Management manages hedge funds and private equity funds that focus on investments in healthcare and life sciences companies. The firm invests globally, with emphasis on the stocks of small-cap healthcare technology companies. | Finance |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Finance |
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
BioVision, Inc.
BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kymera Therapeutics, Inc.
 Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Kronos Bio, Inc.
 Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
Stealth BioTherapeutics, Inc.
 Stealth BioTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat the mitochondrial dysfunctions and age-related diseases | Health Technology |
Immunic, Inc.
 Immunic, Inc. Pharmaceuticals: MajorHealth Technology Develops oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases | Health Technology |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
